UBS Group’s Atossa Therapeutics ATOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $484K | Buy |
92,034
+66,033
| +254% | +$418K | ﹤0.01% | 6109 |
|
|
2025
Q4 | $230K | Buy |
26,001
+8,620
| +50% | +$109K | ﹤0.01% | 6503 |
|
|
2025
Q3 | $226K | Sell |
17,381
-10,116
| -37% | -$125K | ﹤0.01% | 6605 |
|
|
2025
Q2 | $342K | Sell |
27,497
-2,862
| -9% | -$34.2K | ﹤0.01% | 6334 |
|
|
2025
Q1 | $306K | Sell |
30,359
-44,621
| -60% | -$542K | ﹤0.01% | 6225 |
|
|
2024
Q4 | $1.06M | Buy |
74,980
+70,260
| +1,489% | +$1.37M | ﹤0.01% | 5252 |
|
|
2024
Q3 | $108K | Buy |
4,720
+1,957
| +71% | +$39.5K | ﹤0.01% | 6307 |
|
|
2024
Q2 | $49.3K | Buy |
2,763
+2,735
| +9,768% | +$60.5K | ﹤0.01% | 6702 |
|
|
2024
Q1 | $761 | Buy |
28
+26
| +1,300% | +$418 | ﹤0.01% | 8374 |
|
|
2023
Q4 | $26 | Sell |
2
-2,222
| -100% | -$24K | ﹤0.01% | 9053 |
|
|
2023
Q3 | $24.6K | Buy |
+2,224
| New | +$32.3K | ﹤0.01% | 6692 |
|
|
2022
Q4 | – | Sell |
-24
| Closed | – | – | 10712 |
|
|
2022
Q3 | $0 | Sell |
24
-362
| -94% | -$5.26K | ﹤0.01% | 10312 |
|
|
2022
Q2 | $6K | Sell |
386
-2,020
| -84% | -$31.8K | ﹤0.01% | 8652 |
|
|
2022
Q1 | $45K | Sell |
2,406
-2,449
| -50% | -$49.8K | ﹤0.01% | 6594 |
|
|
2021
Q4 | $117K | Buy |
4,855
+2,144
| +79% | +$78.5K | ﹤0.01% | 6157 |
|
|
2021
Q3 | $133K | Buy |
+2,711
| New | +$158K | ﹤0.01% | 5622 |
|
|
2021
Q2 | – | Sell |
-1,745
| Closed | -$55K | – | 9369 |
|
|
2021
Q1 | $55K | Buy |
+1,745
| New | +$63.8K | ﹤0.01% | 6443 |
|
|
2020
Q4 | – | Sell |
-257
| Closed | -$9K | – | 8369 |
|
|
2020
Q3 | $9K | Buy |
257
+151
| +142% | +$7.25K | ﹤0.01% | 6913 |
|
|
2020
Q2 | $6K | Buy |
+106
| New | +$3.76K | ﹤0.01% | 7279 |
|
|
2020
Q1 | – | Sell |
-400
| Closed | -$9K | – | 7943 |
|
|
2019
Q4 | $9K | Buy |
400
+306
| +326% | +$7.18K | ﹤0.01% | 7327 |
|
|
2019
Q3 | $3K | Buy |
+94
| New | +$2.98K | ﹤0.01% | 7618 |
|
|
2019
Q1 | – | Sell |
-317
| Closed | -$5K | – | 7716 |
|
|
2018
Q4 | $5K | Buy |
+317
| New | +$6.27K | ﹤0.01% | 7536 |
|
|
2018
Q3 | – | Sell |
-609
| Closed | -$20K | – | 7959 |
|
|
2018
Q2 | $20K | Buy |
609
+393
| +182% | +$21.1K | ﹤0.01% | 6686 |
|
|
2018
Q1 | $17K | Buy |
216
+92
| +74% | +$8.57K | ﹤0.01% | 6496 |
|
|
2017
Q4 | $6K | Buy |
124
+35
| +39% | +$2.55K | ﹤0.01% | 7286 |
|
|
2017
Q3 | $9K | Buy |
+89
| New | +$7.07K | ﹤0.01% | 6937 |
|
|
2017
Q2 | – | Sell |
-38
| Closed | -$3.91K | – | 7647 |
|
|
2017
Q1 | $5K | Buy |
+38
| New | +$9.7K | ﹤0.01% | 6971 |
|
|
2016
Q4 | – | Sell |
-28
| Closed | -$8.73K | – | 7758 |
|
|
2016
Q3 | $10K | Buy |
+28
| New | +$16.8K | ﹤0.01% | 6772 |
|
|
2016
Q2 | – | Sell |
-12
| Closed | -$9.72K | – | 7707 |
|
|
2016
Q1 | $11K | Buy |
12
+8
| +200% | +$7.41K | ﹤0.01% | 6590 |
|
|
2015
Q4 | $3K | Sell |
4
-1
| -20% | -$1.54K | ﹤0.01% | 7862 |
|
|
2015
Q3 | $11K | Buy |
+5
| New | +$12.8K | ﹤0.01% | 7191 |
|
|
2015
Q1 | – | Hold |
0
| – | -$1K | – | 8790 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 9522 |
|
Other funds holding ATOS
VCM
VFT
UBS Group's ATOS Position: Q1 2026 in Review
UBS Group increased its Atossa Therapeutics (ATOS) stake by 254% in Q1 2026, buying an estimated $418K and bringing the position to 92,034 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #6109.
UBS Group first reported a position in ATOS in Q3 2015 and has held it in 31 quarters since. The position peaked at $1.06M in Q4 2024. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.
- UBS Group held 92,034 shares of Atossa Therapeutics worth $484K as of Q1 2026.
- UBS Group bought 66,033 Atossa Therapeutics shares in Q1 2026, an estimated $418K.
- Atossa Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6109 holding.
- UBS Group first reported a position in Atossa Therapeutics in Q3 2015 and has held it in 31 quarters since.
- UBS Group's Atossa Therapeutics position peaked at $1.06M in Q4 2024.
- 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.